Policy· June 30, 2026 · 17 min read
IRA Medicare Drug Negotiation Proposed Rule: Market-Access Analysis
By Ran Chen#IRA Negotiation#CMS#Market Access
Topic
IRA Negotiation
Medicare drug price negotiation, selected-drug lists, maximum fair price, and downstream lifecycle planning.
Generics· June 23, 2026 · 17 min read
Eliquis Generic: Why US Entry is Delayed to April 2028 Despite IRA Cuts
By Ran Chen#Generic Entry#FDA Approval#Orange Book
Policy· June 21, 2026 · 7 min read
Sitagliptin's May 2026 Generic Launch and Januvia's IRA MFP Termination
Pricing & Access· June 10, 2026 · 10 min read
PD-1/PD-L1 checkpoint inhibitor access landscape in 2026
Policy· June 10, 2026 · 8 min read
The 2026–2032 patent cliff by the numbers: 11,000 patents, $200 billion at risk
By Ran Chen#Orange Book#Generic Entry#Biosimilars
Policy· June 9, 2026 · 12 min read
IRA Medicare drug negotiation third cycle: 15 drugs selected for 2028
Pricing & Access· June 6, 2026 · 12 min read
Medicare Part D GLP-1 coverage 2026: Bridge program, $2,100 cap, and indications
By Ran Chen#GLP-1#Medicare Part D#Prior Authorization
Pricing & Access· June 1, 2026 · 12 min read
IRA Part B drug negotiation: provider reimbursement risk under the buy-and-bill model
Pricing & Access· May 31, 2026 · 9 min read
IRA MFP formulary inclusion exception: successor products and plan design
Pricing & Access· May 31, 2026 · 15 min read
Medicare GLP-1 Bridge PA evidence file and documentation
By Ran Chen#GLP-1#Medicare Part D#Prior Authorization